Skip to main content
Funded Studies

Andrew Edward Parker, BSc, PhD

VP of Pre-Clinical Research at Opsona Therapeutics LTD

Location: Dublin Ireland

Dr Parker leads Opsona’s research projects in inflammation and immunology with a particular focus on Toll like receptors and the role they play in innate immunity. He has extensive experience in the pharmaceutical industry, working for over ten years in the Respiratory and Inflammation Research Area at AstraZeneca, Alderley Park, UK, most recently as Head of In Vitro Pharmacology. Prior to this Andy spent two years with Janssen Pharmaceutica, Beerse, Belgium in the Functional Genomics Group. Andy has directed large research groups and led drug discovery projects from target identification through to candidate drug nomination and early development. Current research interests are in understanding the role of TLR2 in inflammatory processes and diseases.

Associated Grants

  • Development of Anti-toll-like Receptor (TLR)-2 Monoclonal Antibody as a Therapeutic Agent in Parkinson's Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.